Login / Signup

AKT1E17K -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363.

Peter JohnNatalie WaldtJosephine LiebichChristoph KesselerStefan SchnabelFrank AngensteinI Erol SandalciogluCordula ScherlachFelix SahmElmar KirchesChristian Mawrin
Published in: Neuropathology and applied neurobiology (2021)
Our data suggest that AKT1E17K mutated meningiomas are a promising selective target for AZD5363.
Keyphrases
  • signaling pathway
  • cell proliferation
  • big data
  • replacement therapy
  • deep learning
  • optical coherence tomography